Vaccine is intended to stimulate T cell responses against targets across the entire genome of the selected virus, similar to company’s lead product candidate TVGN 489, to mitigate the risk posed by mutations.Approach may provide prophylaxis to viral infections and would be complementary to current treatment under development by Tevogen Bio.Powered by Tevogen Bio’s artificial intelligence initiative, Tevogen.AI.The company hopes to address public concerns about inoculation during vaccine development. WARREN, ...